Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

NCT00331955 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: doxorubicin hydrochloride
DRUG: vorinostat
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)